The Largest Personal Injury Firm in Texas. Serving Clients Nationwide.
Corpus Christi 361-254-7873 San Antonio 210-874-2615 Nationwide Toll Free 866-517-5659
Contact us 24/7 Contact us 24/7

Thomas J. Henry Investigating Kidney Failure in BMS-986094 Studies

View all

CORPUS CHRISTI, TX (May 17, 2013) –Thomas J. Henry is investigating cases of renal failure, some resulting in the need for dialysis, in patients enrolled in the Bristol Myers Squibb BMS-986094 clinical trials for Hepatitis C.

Thomas J. Henry is representing victims across the United States who were injured in the BMS-986094 clinical trials. The firm continues to investigate the drug’s rocky journey toward FDA approval, which began with Inhibitex purchasing the development rights from Cardiff University in 2007 (Inhibitex was subsequently bought out by Bristol Myers Squibb in 2012) and ended abruptly in September 2012 when a patient died of heart failure during a BMS Phase II clinical trial for the drug.

BMS-986094 (formerly known as INX-08189) was being tested on humans in Phase II of a clinical trial when the study was suspended early amid reports of one death and eight other patient hospitalizations, some for heart and kidney toxicity.


  • Fatigue
  • Nausea/vomiting
  • Shortness of breath
  • Decreased urine production
  • Kidney damage
  • Renal Failure
  • Swelling of the legs
  • Feelings of anxiety
  • Heart palpitations
  • Chest pain
  • Abnormal heart rhythm
  • Valve inflammation
  • Cardiomyopathy
  • Heart damage
  • Heart attack
  • Heart failure
  • Death


Locations of the BMS-986094 trials include:

  • Montgomery, AL
  • Augusta, GA
  • Asheville, NC
  • Tulsa, OK
  • Arlington, TX
  • Hoover, AL
  • Anaheim, CA
  • La Jolla, CA
  • San Diego, CA
  • San Francisco, CA
  • Orlando, FL
  • Atlanta, GA
  • New York, NY
  • Portland, OR
  • Austin, TX
  • San Antonio, TX
  • Fairfax, VA
  • Newport News, VA
  • Seattle, WA


Do you really want to end conversation?
chat-icon Live chat
avatar Waiting